| ARROWHEAD PHARMACEUTICALS |
| USA |
| Gesundheit |
| US04280A1007 / A2AGYB |
| HDP1 (Frankfurt) / ARWR (NASDAQ) |
| FRA:HDP1, ETR:HDP1, HDP1:GR, NASDAQ:ARWR |
| - |
| https://arrowheadpharma.c.. |
|
Arrowhead Pharmaceuticals is a biotechnology company focused on developing innovative medicines for intractable diseases. The company specializes in RNA interference (RNAi) therapeutics, a cutting-edge approach to treating genetic and metabolic disor..
>Volltext.. |
| 8273.98 Mio. EUR |
| 8074.02 Mio. EUR |
| 927.38 Mio. EUR |
| 276.82 Mio. EUR |
| 171.93 Mio. EUR |
| 1.33 EUR |
| 584.63 Mio. EUR |
| 171.4 Mio. EUR |
| 292.67 Mio. EUR |
| 2.64 |
| 38363.88% |
| - |
| - |
| - |
| - |
| - |
| ARROWHEAD PHARMACEUTICALS, ARROWHEAD PHARMA, ARROWHEAD PHARMACEUTICAL |
| 21.04.26 |